MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced that the United States Food and Drug Administration (FDA) has granted Fast…
Read More...
Read More...